Photo of Xiaoban Xin

With years of experience as a biomedical researcher, Dr. Xiaoban Xin assists companies and research institutes with building, managing, and protecting their patent assets, strategic patent counseling, and due diligence.  Xiaoban has specific experience working with clients in the fields of biotechnology, including gene editing (e.g., CRISPR technology), next generation sequencing, immunotherapy, cell therapy, biologics, stem cells, genetically modified animals, and pharmaceutical formulations, as well as medical device and health IT.

On January 28, 2021, Bio-Thera Solutions, Ltd., a biopharmaceutical company based in China, announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to bevacizumab, referencing Genentech’s Avastin®, but excluding indications under orphan drug exclusivity protection.  The FDA has set November 27, 2021,